BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 29389078)

  • 1. Systemic Pharmacokinetics, Safety, and Preliminary Efficacy of Topical AhR Agonist Tapinarof: Results of a Phase 1 Study.
    Bissonnette R; Vasist LS; Bullman JN; Collingwood T; Chen G; Maeda-Chubachi T
    Clin Pharmacol Drug Dev; 2018 Jun; 7(5):524-531. PubMed ID: 29389078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and patient-reported outcomes from a phase 2b, randomized clinical trial of tapinarof cream for the treatment of adolescents and adults with atopic dermatitis.
    Paller AS; Stein Gold L; Soung J; Tallman AM; Rubenstein DS; Gooderham M
    J Am Acad Dermatol; 2021 Mar; 84(3):632-638. PubMed ID: 32502588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase 2b, randomized clinical trial of tapinarof cream for the treatment of plaque psoriasis: Secondary efficacy and patient-reported outcomes.
    Stein Gold L; Bhatia N; Tallman AM; Rubenstein DS
    J Am Acad Dermatol; 2021 Mar; 84(3):624-631. PubMed ID: 32446832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis.
    Lebwohl MG; Stein Gold L; Strober B; Papp KA; Armstrong AW; Bagel J; Kircik L; Ehst B; Hong HC; Soung J; Fromowitz J; Guenthner S; Piscitelli SC; Rubenstein DS; Brown PM; Tallman AM; Bissonnette R
    N Engl J Med; 2021 Dec; 385(24):2219-2229. PubMed ID: 34879448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tapinarof Is a Natural AhR Agonist that Resolves Skin Inflammation in Mice and Humans.
    Smith SH; Jayawickreme C; Rickard DJ; Nicodeme E; Bui T; Simmons C; Coquery CM; Neil J; Pryor WM; Mayhew D; Rajpal DK; Creech K; Furst S; Lee J; Wu D; Rastinejad F; Willson TM; Viviani F; Morris DC; Moore JT; Cote-Sierra J
    J Invest Dermatol; 2017 Oct; 137(10):2110-2119. PubMed ID: 28595996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of atopic dermatitis.
    Peppers J; Paller AS; Maeda-Chubachi T; Wu S; Robbins K; Gallagher K; Kraus JE
    J Am Acad Dermatol; 2019 Jan; 80(1):89-98.e3. PubMed ID: 30554600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tapinarof Cream 1% for Extensive Plaque Psoriasis: A Maximal Use Trial on Safety, Tolerability, and Pharmacokinetics.
    Jett JE; McLaughlin M; Lee MS; Parish LC; DuBois J; Raoof TJ; Tabolt G; Wilson T; Somerville MC; DellaMaestra W; Piscitelli SC
    Am J Clin Dermatol; 2022 Jan; 23(1):83-91. PubMed ID: 34713415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tapinarof Cream 1%: First Approval.
    Keam SJ
    Drugs; 2022 Jul; 82(11):1221-1228. PubMed ID: 35939180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topical Agents Currently in Phase II or Phase III Trials for Atopic Dermatitis.
    Uppal SK; Chat VS; Kearns DG; Wu JJ
    J Drugs Dermatol; 2020 Oct; 19(10):956-959. PubMed ID: 33026767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of plaque psoriasis.
    Robbins K; Bissonnette R; Maeda-Chubachi T; Ye L; Peppers J; Gallagher K; Kraus JE
    J Am Acad Dermatol; 2019 Mar; 80(3):714-721. PubMed ID: 30612986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of topical WBI-1001 in patients with mild to severe atopic dermatitis: results from a 12-week, multicentre, randomized, placebo-controlled double-blind trial.
    Bissonnette R; Poulin Y; Zhou Y; Tan J; Hong HC; Webster J; Ip W; Tang L; Lyle M
    Br J Dermatol; 2012 Apr; 166(4):853-60. PubMed ID: 22182053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized, double-blind, placebo-controlled, multiple-dose study of the safety, tolerability and pharmacokinetics of benvitimod, a candidate drug for the treatment of psoriasis.
    Zhao L; Chen X; Cai L; Zhang C; Wang Q; Jing S; Chen G; Li J; Zhang J; Fang Y
    J Clin Pharm Ther; 2014 Aug; 39(4):418-23. PubMed ID: 24673513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tapinarof, a Novel, First-in-Class, Topical Therapeutic Aryl Hydrocarbon Receptor Agonist for the Management of Psoriasis.
    Bobonich M; Gorelick J; Aldredge L; Bruno MJ; DiRuggiero D; Martin G; Tallman AM; Gold LS
    J Drugs Dermatol; 2023 Aug; 22(8):779-784. PubMed ID: 37556512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the Aryl Hydrocarbon Receptor to Address the Challenges of Atopic Dermatitis.
    Eichenfield LF; Silverberg JI; Hebert AA; Chovatiya R; Brown PM; McHale KA; Rubenstein DS; Tallman AM
    J Drugs Dermatol; 2024 Feb; 23(2):23-28. PubMed ID: 38306128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tapinarof to treat psoriasis.
    Rodríguez Baisi K; Tollefson M
    Drugs Today (Barc); 2020 Aug; 56(8):515-530. PubMed ID: 33025947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tapinarof cream 1% once daily for the treatment of adults with mild to severe plaque psoriasis: A novel topical therapy targeting the aryl hydrocarbon receptor.
    Armstrong AW; McConaha JL
    J Manag Care Spec Pharm; 2023 Dec; 29(12-a Suppl):S2-S14. PubMed ID: 38014659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tapinarof cream 1% once daily for the treatment of adults with mild to severe plaque psoriasis: A novel topical therapy targeting the aryl hydrocarbon receptor.
    Armstrong AW; McConaha JL
    J Manag Care Spec Pharm; 2023 Dec; 29(12-a Suppl):S1-S13. PubMed ID: 38051146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tapinarof in the treatment of psoriasis: A review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor-modulating agent.
    Bissonnette R; Stein Gold L; Rubenstein DS; Tallman AM; Armstrong A
    J Am Acad Dermatol; 2021 Apr; 84(4):1059-1067. PubMed ID: 33157177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: Results from the PSOARING 3 trial.
    Strober B; Stein Gold L; Bissonnette R; Armstrong AW; Kircik L; Tyring SK; Piscitelli SC; Brown PM; Rubenstein DS; Tallman AM; Lebwohl MG
    J Am Acad Dermatol; 2022 Oct; 87(4):800-806. PubMed ID: 35772599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tapinarof for psoriasis and atopic dermatitis: 15 years of clinical research.
    Bissonnette R; Saint-Cyr Proulx E; Jack C; Maari C
    J Eur Acad Dermatol Venereol; 2023 Jun; 37(6):1168-1174. PubMed ID: 36708084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.